Search Results
Jan 22, 2026, 12:30 ET Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
CORAL) trial was a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of nalbuphine ER (27 mg, 54 mg, and 108 mg twice daily) compared to placebo for the treatment of chronic cough in patients with IPF over a 6-week treatment period. 165 patients with IPF
More news about: Trevi Therapeutics, Inc.
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms." In light of the trial results, Insmed decided to discontinue development of brensocatib. On this news, Insmed's stock price
More news about: Pomerantz LLP
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
hypoglycemia events by self monitored blood glucose. There was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement. Furthermore, the study did not meet its
More news about: Pomerantz LLP
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
hypoglycemia events by self monitored blood glucose. There was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement. Furthermore, the study did not meet its
More news about: Pomerantz LLP
Jan 22, 2026, 08:01 ET CoreAge Rx Introduces Flat-Rate Pricing for GLP-1 Medications
spokesperson for CoreAge Rx. "Our transparent pricing model means patients know exactly what they'll pay from the start. Whether you're taking 2.5mg or 15mg of tirzepatide, the annual cost remains the same. No surprises."The company's streamlined process allows patients to complete a brief online
More news about: CoreAge Rx
Jan 21, 2026, 08:31 ET Vestibular da Faculdade de Medicina Moinhos de Vento tem inscrições abertas até 26 de janeiro
instituição e também da Fundação Vunesp. A prova presencial será aplicada no dia 22 de fevereiro, das 14h às 19h, em sete capitais brasileiras: Belo Horizonte/MG, Brasília/DF, Curitiba/PR, Florianópolis/SC, Porto Alegre/RS, Rio de Janeiro/RJ e São Paulo/SP.Ao todo, serão ofertadas 60 vagas neste primeiro
More news about: Hospital Moinhos de Vento
Jan 20, 2026, 19:00 ET Rakuten Medical Expands Academic Access to IR700 Dye Through Fee-Only Provision, Greater Publication Freedom and Expanded IP & Commercialization Opportunities
multiple pre-clinical and clinical programs involving the company's investigational and commercial drug assets. Among these is Akalux™ IV Infusion 250 mg, which is approved in Japan for unresectable locally advanced or recurrent head and neck cancer. Photoimmunotherapy with Akalux has been provided more
More news about: Rakuten Medical, Inc.
Jan 20, 2026, 12:41 ET OCuSOFT Inc. Launches Retaine® Omega Forté™ Liquid Supplement for Superior Nutritional Support in Dry Eye Management
clinical performance in mind, Retaine® Omega Forté™ delivers a potent daily dose of omega-3 essential fatty acids—2,490 mg of EPA and DHA, plus 405 mg of additional omega-3s—in a convenient, lemon-flavored liquid that leaves no fishy aftertaste.Retaine® Omega Forté™
More news about: OCuSOFT Inc.
Jan 20, 2026, 09:00 ET Novo Nordisk introduces "There's Only One Ozempic®" campaign, reuniting Justin Long and John Hodgman
2026 /PRNewswire/ -- Novo Nordisk today announced the launch of a new consumer campaign for Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, reinventing how traditional pharma advertising is being done. The campaign features the celebrated comedy pairing of actors Justin Long and John
More news about: Novo Nordisk
Jan 20, 2026, 09:00 ET Tanabe Pharma America Announces Positive Topline Results for Dersimelagon in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
16-week double-blind treatment period, in which participants are randomly assigned to either the placebo group or active treatment group (dersimelagon 200 mg once daily), followed by a 36-week open-label extension period of active treatment. The study met the primary endpoint, which is the time to first prodromal
More news about: Tanabe Pharma America
Jan 20, 2026, 09:00 ET Introducing VSL4® Vaginal Health: A Precision-Formulated, Next-Gen Daily Supplement for Women
FiberEssential B & D Vitamins: Vitamin D3, Riboflavin, FolateWhole Fruit Cranberry Extract: 200:1 concentrate equivalent to 4300 mg of fresh cranberries"As an OB-GYN, it's crucial that women have the right tools that truly support their overall wellness, especially when
More news about: VSL
Jan 20, 2026, 08:33 ET Ryde: Raises the Bar on Supplement Transparency with New Informed Choice Certification
cure, or prevent any disease. Not recommended for individuals under the age of 18 or those sensitive to caffeine. Focus includes 150 mg caffeine and Energize includes 200 mg of caffeine. Do not consume more than two shots per day or in combination. Please check label before consumption to see if Ryde: is
More news about: Ryde
Jan 20, 2026, 08:04 ET THE ABSORPTION COMPANY LAUNCHES NEXT-GEN SINGLE SUPPLEMENTS ENGINEERED FOR MAXIMUM ABSORPTION
lost to poor bioavailability. Powered by clinically studied Curcuwin® Ultra+, this formula is absorbed 149X better, delivers the equivalent of 14,222 mg of standard curcumin, and supports joint comfort and recovery with results in as little as five days."Our mission is simple: deliver real benefits
More news about: The Absorption Company
Jan 19, 2026, 20:00 ET Greenberg Traurig Expands APAC Private Credit and Restructuring Capabilities with Singapore Hire of Former M&G Head of Restructuring Andrew Amos
multimedia:https://www.prnewswire.com/news-releases/greenberg-traurig-expands-apac-private-credit-and-restructuring-capabilities-with-singapore-hire-of-former-mg-head-of-restructuring-andrew-amos-302663143.htmlSOURCE
More news about: Greenberg Traurig, LLP
Jan 19, 2026, 08:29 ET MSI Celebrates Republic Day with Tricolor of Technology Offers
69,990.00Prestige 16 AI Evo B1MG-054INIntel® Core™ Ultra 7/Intel® Arc™ graphics/16GB
More news about: MSI
Jan 19, 2026, 07:07 ET THE WAIT IS OVER: RED BULL® ICED EDITION AND RED BULL PEACH EDITION ARE HERE TO STAY
178 countries worldwide, and more than 12.6 billion cans of Red Bull were consumed in 2024 alone. An 8.4 fl oz can of Red Bull Energy Drink contains 80mg of caffeine, about the same as in a home-brewed cup of coffee. For more information, visit
More news about: Red Bull
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
combination study of givastomig with 77% ORR at 8 mg/kg and 73% ORR at 12 mg/kg in first-line HER2-negative metastatic gastric cancer patients. The global biotechnology platform company reported median progression-free survival of 16.9 months at 8 mg/kg, with the CLDN18.2 x 4-1BB bispecific antibody demonstrating
More news about: Equity Insider
Jan 16, 2026, 08:00 ET New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
www.fda.gov/medwatch.CAPLYTA is available in 42 mg, 21 mg, and 10.5 mg capsules.US-CAP-2500827Please see full
More news about: Johnson & Johnson
Jan 15, 2026, 20:00 ET Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
2+ > 20%) in the 2.4 mg/kg dose cohort, the objective response rate (ORR) was 40% (12/30) and the disease control rate (DCR) was 90% (27/30), with a median progression-free survival (mPFS) of 5.09 months and a median overall survival (mOS) of 14.72 months. In the 1.8 mg/kg dose cohort, the
More news about: Antengene Corporation Limited
Jan 15, 2026, 14:07 ET Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
surgery or curative radiation.It is not known if UNLOXCYT is safe and effective in children.The recommended dosage of UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks.IMPORTANT SAFETY INFORMATIONWARNING AND PRECAUTIONSImmune-mediated
More news about: Sun Pharma
Jan 15, 2026, 12:57 ET Volkswagen ganha mercado e lidera vendas de caminhões em 2025
[email protected] - https://mma.prnewswire.com/media/2862939/MG_3194.jpg
More news about: Volkswagen Caminhões e Ônibus
Jan 15, 2026, 12:02 ET Yamaha Launches MGX Digital Mixer Series, URX Series Audio Interface, and CC1 USB Controller to Empower Musicians, Performers, Streamers, and Content Creators Worldwide
MGX Series: Digital Innovation Meets Trusted HeritageAcclaimed for exceptional sound quality and intuitive design, the Yamaha MG Series mixers have become an industry standard. Building on this legacy, the MGX Series introduces advanced digital technology for superior sound and
More news about: Yamaha
Jan 15, 2026, 10:14 ET Kuli Kuli Debuts Pure Organic Moringa Capsules as Moringa Emerges as a Top Wellness Trend for 2026
incredible plant."Each bottle of Kuli Kuli's Pure Organic Moringa Capsules includes a 30-day supply, with just two capsules delivering over 1,000 mg of organic moringa leaf powder offering an efficient, travel friendly, and approachable format for anyone looking to boost daily energy, digestion, and
More news about: Kuli Kuli Foods
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms." In light of the trial results, Insmed decided to discontinue development of brensocatib. On this news, Insmed's stock price
More news about: Pomerantz LLP
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
hypoglycemia events by self monitored blood glucose. There was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement. Furthermore, the study did not meet its
More news about: Pomerantz LLP